Cyclic compounds having a cycloalkylene chain
AssigneeLes Laboratoires Servier
InventorsMichel Langlois, Monique Mathe-Allainmat, Marie Lefas-Le Gall, Caroline Bennejean, Pierre Renard, Philippe Delagrange
Life of this patent
Estimating the term…
Abstract
The invention relates to compounds of for a (I): wherein: R represents ORa, SRa or Ra or a cyclic group A is a cyclic structure G1 and G2 represent an alkylene chain or a single bond B represents —NR1aC(Q)R2a, —NR1aC(Q)NR2aR3a or C(Q)NR1aR2a p and q are such that 1≦p+q≦4, and medicinal products containing the same which are useful in treating or in preventing melatoninergic disorders.
Claims20
A compound selected from those of formula (I):
- wherein
- A represents:
- a ring system of formula (II):
- wherein X and Y, which may be identical or different, represent oxygen, sulphur or CH2,
- D represents a benzene ring or a naphthalene ring,
- and the symbol means that the bonds may be single or double, with the proviso that the valency of the atoms is respected,
- wherein R substitutes either the ring system D or the ring containing X and Y, and G1 substitutes the ring containing X and Y,
- or a ring system of formula (III):
- wherein Z represents oxygen, sulphur, CH2, or NR1 (wherein R1 represents hydrogen, linear or branched (C1-C6)alkyl, aryl, or aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched),
- D′ represents a benzene ring or a pyridine ring, and the symbol is as defined hereinabove,
- wherein R substitutes the D′ ring and G1 substitutes the other ring,
- it being understood that the ring systems of formula (II) or (III) may be substituted, in addition to R and G1, by from one to three identical or different groups selected from Ra, ORa, hydroxyl, CORa, formyl, COORa, carboxyl, and OCORa,
- wherein Ra represents substituted or unsubstituted linear or branched (C1-C6)alkyl, substituted or unsubstituted linear or branched (C2-C6)alkenyl, substituted or unsubstituted linear or branched (C2-C6)alkynyl, linear or branched polyhalo-(C1-C6)alkyl, substituted or unsubstituted (C3-C8)-cycloalkyl, substituted or unsubstituted (C3-C8)cycloalkyl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, substituted or unsubstituted (C3-C8)cycloalkenyl, substituted or unsubstituted (C3-C8)cycloalkenyl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, aryl, aryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched, heteroaryl, or heteroaryl-(C1-C6)alkyl in which the alkyl moiety is linear or branched,
- R represents hydrogen, halogen, hydroxyl, SH, Ra, ORa, or S(O)nRa, wherein n is 0, 1 or 2 and Ra is as defined hereinabove,
- or forms, with the carbon atom carrying it and with an adjacent carbon atom, a ring of formula (IV):
- wherein E represents oxygen or —S(O)n— wherein n is as defined hereinabove,
- wherein the resulting ring contains 5 to 7 atoms, may contain one or more unsaturations and may be substituted by one or more groups selected from linear or branched (C1-C6)alkyl, linear or branched (C1-C6)alkoxy, carboxy, linear or branched (C1-C6)alkoxy-carbonyl, hydroxy, and oxo,
- G1 and G2, which may be identical or different, represent a single bond or an alkylene chain —(CH2)t—(wherein t is 1, 2, 3 or 4), unsubstituted or substituted by one or more identical or different radicals selected from hydroxy, carboxy, formyl, Ra, ORa, COORa, CORa (wherein Ra is as defined hereinabove), and halogen,
- p is 0, 1, 2, 3 or 4,
- q is 0, 1, 2, 3 or 4,
- with 1≦p═q≦4,
- B represents —NR1aC(Q)R2a, —NR1aC(Q)NR2aR3a, or —C(Q)NR1aR2a, wherein, R1a, R2a and R3a, which may be identical or different, can have any of the values of Ra or may represent hydrogen, and Q represents oxygen or sulphur,
- it being understood that:
- the term “substituted” applied to the terms “alkyl”, “alkenyl”, and “alkynyl” means that those are substituted by one or more identical or different radicals selected from hydroxy, linear or branched (C1-C6)alkoxy, linear or branched (C1-C6)alkyl, linear or branched polyhalo-(C1-C6)alkyl, amino, and halogen,
- the term “substituted” applied to the terms “cycloalkyl”, “cycloalkylalkyl”, “cycloalkenyl”, and “cycloalkenylalkyl”, means that the cyclic moiety of those groups is substituted by one or more identical or different radicals selected from hydroxy, linear or branched (C1-C6)alkoxy, linear or branched (C1-C6)alkyl, linear or branched polyhalo-(C1-C6)alkyl, amino, and halogen,
- “aryl” is understood to mean phenyl, naphthyl or biphenyl, or one of those groups substituted by one or more identical or different radicals selected from hydroxy, linear or branched (C1-C6)alkoxy, linear or branched (C1-C6)alkyl, linear or branched polyhalo-(C1-C6)alkyl, cyano, carboxy, linear or branched (C1-C6)alkoxy-carbonyl, nitro, amino, and halogen,
- “heteroaryl” is understood to mean a mono- or poly-cyclic aromatic containing 5 to 10 atoms and containing 1 to 3 hetero atoms selected from nitrogen, oxygen, and sulphur, or one of those groups substituted by one or more identical or different radicals selected from hydroxy, linear or branched (C1-C6)alkoxy, linear or branched (C1-C6)alkyl, linear or branched polyhalo-(C1-C6)alkyl, cyano, carboxy, linear or branched (C1-C6)alkoxy-carbonyl, nitro, amino, and halogen,
- with the proviso that:
- when A represents a naphthalene unsubstituted or substituted by one methoxy or one methyl, G1 and G2 simultaneously represent a single bond, and B represents
- or NHCOMe, it is not possible to have (q=0 and p=4) or (q=4 and p=0),
- when G1 represents a single bond and p+q=1, then A cannot represent a naphthalene substituted by one or more halogen,
- when A represents an indole substituted in the 2-position by
- then B cannot represent an urea,
- when A represents an indole substituted in the 2-position by carboxyl or alkoxycarbonyl, p is 1 and q is 0 (or q is 1 and p is 0), and G1 represents a single bond, then B cannot represent CONHAr wherein Ar represents aryl,
- their enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base.
A pharmaceutical composition useful for treating melatoninergic disorders comprising, as active principle, an effective amount of a compound as claimed in claime 1, together with one or more pharmaceutically-acceptable excipients or vehicles.
Dependencies are inferred from the claim text.